Clinical trials
Relapsed or Refractory Multiple Myeloma clinical trials
Below are recruiting relapsed or refractory multiple myeloma clinical trials, each written for real people, not researchers. We’re tracking 1,274 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06660420RecruitingPhase 1
PRAME-targeted NK cells for advanced melanoma
This trial tests a new type of cell therapy using your own immune cells (NK cells) modified to target a protein called PRAME found on melanoma cells. It is for people whose melanoma has not responded to or has returned after standard immunotherapies.
Houston, TexasAges 18 years+ - NCT06641648RecruitingPhase 1
Donor NK cells with low-dose IL-2 for AML relapse after stem cell transplant
This trial tests a new treatment for patients whose acute myeloid leukemia (AML) has come back after a stem cell transplant. It uses immune cells from the original donor, combined with a low dose of a protein called IL-2, to try to fight the leukemia without causing severe side effects.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04598399Recruiting
Mindfulness program for alcohol relapse prevention
This study compares two non-medication programs to help people with alcohol use disorder stay away from relapse. It tests whether mindfulness-based relapse prevention works better than relaxation meditation without a guide.
AngersAges 18 years+ - NCT06554340Recruiting
Exercise study for multiple sclerosis with high blood pressure
This study tests if exercise can improve blood vessel health and daily function in people with multiple sclerosis (MS) who also have high blood pressure. It may help you move better and feel better.
Boston, MassachusettsAges 18 years+ - NCT06592703RecruitingPhase 1
Stem cells for primary progressive MS
This study tests whether stem cells from donated fat tissue can slow down primary progressive multiple sclerosis. You would receive a single injection of the cells into your spinal fluid and be followed for up to 2 years.
CréteilAges 18–55 - NCT06599580Recruiting
Checking kids' arm measurements to prevent relapse after malnutrition recovery
This study tests whether measuring a caregiver's arm width can help predict if a child who recently recovered from severe malnutrition will become malnourished again. It aims to find ways to catch problems early and keep children healthy.
NounaAges 6 months–4.5 years - NCT06599307RecruitingPhase 2
Rituximab for thinking and hand function in advanced MS
This trial tests whether the drug rituximab can help people with secondary progressive MS keep their thinking and hand abilities from getting worse. It is for people with more advanced disability.
Giza, Giza GovernorateAges 18 years+ - NCT06552416RecruitingPhase 1
Safety study of MT-401-OTS for relapsed AML or MDS
This trial tests a new cell therapy called MT-401-OTS for people aged 65 or older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. The goal is to see if this treatment is safe and to find the right dose.
Duarte, CaliforniaAges 65 years+ - NCT06553053Recruiting
Acupuncture to prevent Crohn's disease relapse
This trial tests if acupuncture can help people with Crohn's disease stay in remission longer and avoid flare-ups. If you are in remission but have had frequent relapses, this study may be for you.
ShanghaiAges 16–75 - NCT04694534Recruiting
Serious game program to help thinking skills in multiple sclerosis
This trial tests whether a computer “serious game” can improve thinking and memory skills in people with multiple sclerosis (MS). It’s designed for adults who report thinking problems and show weaker-than-average results on specific brain tests.
Arras, Hauts-de-FranceAges 18–65 - NCT06513429Recruiting
IM19 CAR-T cell therapy for tough lupus cases
This trial tests whether a new type of immune cell therapy, called IM19 CAR-T, can help people with lupus that hasn't gotten better with standard treatments. It is designed for people ages 18 to 65 with moderate to severe disease activity.
Beijing, Beijing MunicipalityAges 18–65 - NCT06463743RecruitingPhase 2
Metformin for aging people with MS
This study tests whether metformin, a common diabetes drug, can help people with multiple sclerosis (MS) as they age. It may be used alone or added to your current MS treatment, and the goal is to see if it slows down aging-related changes in MS.
Buffalo, New YorkAges 55–75 - NCT06386315RecruitingPhase 2
Lower dose radiation for slow-growing lymphoma
This trial tests whether giving a lower dose of radiation than usual works well for people with slow-growing B-cell lymphomas. It aims to reduce side effects while still controlling the disease.
Scottsdale, ArizonaAges 18 years+ - NCT06343792RecruitingPhase 2
Testing RLS-0071 for steroid-resistant acute graft-versus-host disease
This trial tests a new drug, RLS-0071, for people who are hospitalized with acute graft-versus-host disease that hasn't improved with steroids. It aims to see if the drug is safe and can help control the condition.
Duarte, CaliforniaAges 12 years+ - NCT06341023Recruiting
Balance training for older adults with MS
This study tests a balance training program for people with MS who have mild walking and memory difficulties. It aims to improve balance and prevent falls.
Chicago, IllinoisAges 18–90 - NCT04121468RecruitingPhase 1/Phase 2
Metformin trial for vision nerve recovery in young people with MS
This study tests whether metformin can help “reset” damaged nerve cells in the brain and improve vision-related nerve problems in children and young adults with multiple sclerosis. Participants are assigned to metformin or a comparison treatment in a blinded (not everyone knows which) study.
Toronto, OntarioAges 10–25 - NCT06280742Recruiting
Brain inflammation in multiple sclerosis: a PET-MRI imaging study
This study uses a special PET-MRI scan to look at brain inflammation in people with relapsing-remitting multiple sclerosis (RRMS). It may help researchers understand how inflammation changes when starting a stronger MS treatment.
LyonAges 18 years+ - NCT06261528Enrolling by invitationPhase 1
Light therapy for sleepiness in progressive MS
This trial tests whether a special light therapy can help people with progressive multiple sclerosis who feel sleepy during the day. It aims to improve energy, mood, and sleep patterns.
Dallas, TexasAges 18 years+ - NCT06261489RecruitingPhase 2
Cannabis for bladder problems in multiple sclerosis
This study tests whether cannabis, with either THC or CBD, helps with bladder and urinary symptoms caused by multiple sclerosis. It compares two types of cannabis to see which works better.
Calgary, AlbertaAges 26–59 - NCT06211335RecruitingPhase 1
Losartan, pembrolizumab and radiation for advanced head & neck cancer
This trial tests a combination of three treatments—a blood pressure drug (losartan), an immunotherapy (pembrolizumab), and targeted radiation—for people with head and neck cancer that has come back, spread to a few spots, or is not responding to other treatments. The goal is to see if this mix can shrink tumors and help patients who have few options left.
Sacramento, CaliforniaAges 18 years+ - NCT06221631Recruiting
Brain aging in MS and healthy people
This study compares how the brain ages in people with multiple sclerosis (MS) and healthy volunteers. It uses MRI scans and other tests to understand brain aging better.
Bern, Canton of BernAges 18–65 - NCT06197685Recruiting
Combining treatments to improve memory in multiple sclerosis
This trial tests a combination of two approaches to help people with MS improve memory and learning. If you have mild-to-moderate mobility issues and are not very active, you may be able to join.
East Hanover, New JerseyAges 18–70 - NCT06136728RecruitingPhase 3
Dalfampridine and physical therapy for walking problems in MS
This trial tests whether adding dalfampridine to physical therapy helps people with multiple sclerosis walk better. You must not already be taking dalfampridine or getting physical therapy to join.
Boston, MassachusettsAges 25–75 - NCT06066359RecruitingPhase 1/Phase 2
Cord blood NK cells for NY-ESO-1 positive myeloma
This trial tests a new treatment using cord blood immune cells (NK cells) that are specially designed to target a protein called NY-ESO-1 found on myeloma cells. It is for people with multiple myeloma that has come back or not responded to at least two previous treatments.
Houston, TexasAges 18–80
Hear when a new Relapsed or Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory multiple myeloma?
- Yes. Clin2 currently lists 1,274 recruiting relapsed or refractory multiple myeloma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory multiple myeloma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.